Skip to main navigation Skip to search Skip to main content

Randomized controlled trial of recombinant interferon alfa-2b in chronic NANB hepatitis: Dose schedules and results

  • YF Liaw*
  • , IS Sheen
  • *Corresponding author for this work
  • Chang Gung Memorial Hospital

Research output: Contribution to journalJournal Article peer-review

2 Scopus citations

Abstract

• ■ Response rate: 50-65% (87.5% within 2 months). • ■ Relapse in 80% after down titration, 80% response again on up titration. • ■ Relapse after end of treatment: 55%, usually transient.

Original languageEnglish
Pages (from-to)S160
JournalJournal of Hepatology
Volume11
Issue numberSUPPL. 1
DOIs
StatePublished - 1990
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Randomized controlled trial of recombinant interferon alfa-2b in chronic NANB hepatitis: Dose schedules and results'. Together they form a unique fingerprint.

Cite this